Friday, March 30, 2012

Circumcision Hype?

 A new study linking circumcision before sexual intercourse to lower rates of prostate cancer may be so flawed that the conclusions are meaningless, says Dr. Gerald Chodak.
Medscape Urology

Read the Medscape report here:
Circumcision Hype?

Thursday, March 29, 2012

Self-checking won't spot testicle cancer

'There is no good evidence that routine testicular self-examination is of any benefit, says doctorCelebrity appeals for British men to check their testicles to detect early signs of cancer are a waste of time and possibly harmful, an opinion piece published by the British Medical Journal (BMJ) says.

Read the report here:
Self-checking won't spot testicle cancer

Monday, March 12, 2012

Circumcision tied to lower prostate cancer risk

NEW YORK (Reuters Health) - Circumcised men may have a slightly lower risk of developing prostate cancer than those who still have their foreskin, according to a new study.

The new work falls short of actually proving that removing a boy's foreskin will cut his future cancer risk, said Dr. Jonathan L. Wright, who led the research.

"I would not go out and advocate for widespread circumcision to prevent prostate cancer," Wright, of the Fred Hutchinson Cancer Research Center in Seattle, told Reuters Health."We see an association, but it doesn't prove causality." 



Read the full Reuters Health report:
Circumcision tied to lower prostate cancer risk

Saturday, February 18, 2012

Men opting for costly new prostate cancer treatment

NEW YORK (Reuters Health) -

Men diagnosed with localized prostate cancer are more likely to be treated with proton beam therapy, a novel form of radiation therapy, if the technology is available nearby, a new study found.

In the study, researchers examined the treatment choices of nearly 20,000 men living inside or outside of a regional market for Loma Linda University, a hospital in Southern California with a proton beam facility. All men were diagnosed with low- to intermediate-risk prostate cancer.

The treatment is often billed as having lower impotence and incontinence rates than other radiation treatment options, but there's a lack of evidence to support this.

Despite the added costs, there's no evidence to suggest that proton beam therapy results in better outcomes than other forms of prostate cancer treatment, including other forms of radiation, surgery or hormone therapy.

With the healthcare crisis looming and multiple treatment options available, newer, more expensive procedures for prostate cancer should be validated before they are implemented.

Read the full Reuters Health report:
Men opting for costly new prostate cancer treatment


Thursday, February 16, 2012

In prostate cancer, other death risks may be higher

NEW YORK (Reuters Health) -

Some men with prostate cancer may have increased risks of dying from causes other than the cancer itself, a new study finds.

Researchers found that when men had their prostate cancer diagnosed after developing symptoms -- and not after screening tests -- they had heightened risks of dying from heart problems or other cancers.

It's not clear what to make of the findings at this point. Mainly, they raise questions for future studies, said Dr. Anthony D'Amico, of the Dana-Farber Cancer Institute and Harvard Medical School in Boston.


Read the full Reuters report:
In prostate cancer, other death risks may be higher


DiagnoCure gets FDA nod for prostate cancer test, shares jump

(Reuters) -

Canada's DiagnoCure Inc said it received U.S. regulatory approval for a prostate cancer test that may help avoid unnecessary biopsies, sending its shares to their highest in about 18 months.

The urine-based test -- named Progensa PCA3 -- will be used with other patient information to help decide on repeat biopsy in men of 50 years or older.

The company said the PCA3 test will now be available for sale in the United States, Canada and the European Union.

Read the full Reuters report:
DiagnoCure gets FDA nod for prostate cancer test, shares jump


Saturday, February 11, 2012

Prostate Size May Be Clue to Severity of Cancer


FRIDAY, Feb. 10 (HealthDay News) --

The size of a man's prostate gland may help doctors predict the severity of his prostate cancer, according to a new study.

Researchers from the Vanderbilt-Ingram Cancer Center in Nashville, Tenn., found smaller prostates that produce higher levels of prostate specific antigen (PSA) in the blood are more often linked to serious forms of prostate cancer that require aggressive treatment.

What it's really about is the ratio of PSA to size, or PSA density, meaning that a small prostate that is making a lot of PSA is likely to be due to a bad tumor, whereas a large prostate making a lot of PSA is likely to be due to benign enlargement of the prostate (BPH).

The study's authors suggest the findings could help doctors determine the best course of treatment for patients with prostate cancer. For instance, low-risk patients with a small prostate might benefit from aggressive treatment.

The researchers pointed out that the findings are significant since men with prostate cancer who are considered low-risk may receive less aggressive treatment or just be placed under observation.

The researchers cautioned that more accurate tests are still needed to determine which cancers are actually threatening to patients.


Read the full HealthDay News report:
Prostate Size May Be Clue to Severity of Cancer